Immunomodulatory drugs: Immune checkpoint agents in acute leukemia

Hanna A. Knaus, Christopher G. Kanakry, Leo Luznik, Ivana Gojo

Research output: Research - peer-reviewReview article

Abstract

Intrinsic immune responses to acute leukemia are inhibited by a variety of mechanisms, such as aberrant antigen expression by leukemia cells, secretion of immunosuppressive cytokines and expression of inhibitory enzymes in the tumor microenvironment, expansion of immunoregulatory cells, and activation of immune checkpoint pathways, all leading to T cell dysfunction and/or exhaustion. Leukemic cells, similar to other tumor cells, hijack these inhibitory pathways to evade immune recognition and destruction by cytotoxic T lymphocytes. Thus, blockade of immune checkpoints has emerged as a highly promising approach to augment innate anti-tumor immunity in order to treat malignancies. Most evidence for the clinical efficacy of this immunotherapeutic strategy has been seen in patients with metastatic melanoma, where anti-CTLA-4 and anti-PD-1 antibodies have recently revolutionized treatment of this lethal disease with otherwise limited treatment options. To meet the high demand for new treatment strategies in acute leukemia, clinical testing of these promising therapies is commencing. Herein, we review the biology of multiple inhibitory checkpoints (including CTLA-4, PD-1, TIM-3, LAG-3, BTLA, and CD200R) and their contribution to immune evasion by acute leukemias. In addition, we discuss the current state of preclinical and clinical studies of immune checkpoint inhibition in acute leukemia, which seek to harness the body’s own immune system to fight leukemic cells.

LanguageEnglish (US)
Pages315-331
Number of pages17
JournalCurrent Drug Targets
Volume18
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Leukemia
Pharmaceutical Preparations
Tumors
Therapeutics
T-cells
Neoplasms
Immune system
Immunosuppressive Agents
Chemical activation
Cells
Cytokines
Antigens
Antibodies
Testing
Enzymes
Immune Evasion
Tumor Microenvironment
Cytotoxic T-Lymphocytes
Immune System
Immunity

Keywords

  • Acute lymphoblastic leukemia
  • Acute myeloid leukemia
  • Co-inhibitory receptor
  • Immune checkpoint pathway
  • Immune evasion
  • Immunotherapy
  • Monoclonal antibody
  • T cells

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Immunomodulatory drugs : Immune checkpoint agents in acute leukemia. / Knaus, Hanna A.; Kanakry, Christopher G.; Luznik, Leo; Gojo, Ivana.

In: Current Drug Targets, Vol. 18, No. 3, 01.03.2017, p. 315-331.

Research output: Research - peer-reviewReview article

Knaus, Hanna A. ; Kanakry, Christopher G. ; Luznik, Leo ; Gojo, Ivana. / Immunomodulatory drugs : Immune checkpoint agents in acute leukemia. In: Current Drug Targets. 2017 ; Vol. 18, No. 3. pp. 315-331
@article{aa252c9fb25248b4bff7af29ec974a48,
title = "Immunomodulatory drugs: Immune checkpoint agents in acute leukemia",
abstract = "Intrinsic immune responses to acute leukemia are inhibited by a variety of mechanisms, such as aberrant antigen expression by leukemia cells, secretion of immunosuppressive cytokines and expression of inhibitory enzymes in the tumor microenvironment, expansion of immunoregulatory cells, and activation of immune checkpoint pathways, all leading to T cell dysfunction and/or exhaustion. Leukemic cells, similar to other tumor cells, hijack these inhibitory pathways to evade immune recognition and destruction by cytotoxic T lymphocytes. Thus, blockade of immune checkpoints has emerged as a highly promising approach to augment innate anti-tumor immunity in order to treat malignancies. Most evidence for the clinical efficacy of this immunotherapeutic strategy has been seen in patients with metastatic melanoma, where anti-CTLA-4 and anti-PD-1 antibodies have recently revolutionized treatment of this lethal disease with otherwise limited treatment options. To meet the high demand for new treatment strategies in acute leukemia, clinical testing of these promising therapies is commencing. Herein, we review the biology of multiple inhibitory checkpoints (including CTLA-4, PD-1, TIM-3, LAG-3, BTLA, and CD200R) and their contribution to immune evasion by acute leukemias. In addition, we discuss the current state of preclinical and clinical studies of immune checkpoint inhibition in acute leukemia, which seek to harness the body’s own immune system to fight leukemic cells.",
keywords = "Acute lymphoblastic leukemia, Acute myeloid leukemia, Co-inhibitory receptor, Immune checkpoint pathway, Immune evasion, Immunotherapy, Monoclonal antibody, T cells",
author = "Knaus, {Hanna A.} and Kanakry, {Christopher G.} and Leo Luznik and Ivana Gojo",
year = "2017",
month = "3",
doi = "10.2174/1389450116666150518095346",
volume = "18",
pages = "315--331",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Immunomodulatory drugs

T2 - Current Drug Targets

AU - Knaus,Hanna A.

AU - Kanakry,Christopher G.

AU - Luznik,Leo

AU - Gojo,Ivana

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Intrinsic immune responses to acute leukemia are inhibited by a variety of mechanisms, such as aberrant antigen expression by leukemia cells, secretion of immunosuppressive cytokines and expression of inhibitory enzymes in the tumor microenvironment, expansion of immunoregulatory cells, and activation of immune checkpoint pathways, all leading to T cell dysfunction and/or exhaustion. Leukemic cells, similar to other tumor cells, hijack these inhibitory pathways to evade immune recognition and destruction by cytotoxic T lymphocytes. Thus, blockade of immune checkpoints has emerged as a highly promising approach to augment innate anti-tumor immunity in order to treat malignancies. Most evidence for the clinical efficacy of this immunotherapeutic strategy has been seen in patients with metastatic melanoma, where anti-CTLA-4 and anti-PD-1 antibodies have recently revolutionized treatment of this lethal disease with otherwise limited treatment options. To meet the high demand for new treatment strategies in acute leukemia, clinical testing of these promising therapies is commencing. Herein, we review the biology of multiple inhibitory checkpoints (including CTLA-4, PD-1, TIM-3, LAG-3, BTLA, and CD200R) and their contribution to immune evasion by acute leukemias. In addition, we discuss the current state of preclinical and clinical studies of immune checkpoint inhibition in acute leukemia, which seek to harness the body’s own immune system to fight leukemic cells.

AB - Intrinsic immune responses to acute leukemia are inhibited by a variety of mechanisms, such as aberrant antigen expression by leukemia cells, secretion of immunosuppressive cytokines and expression of inhibitory enzymes in the tumor microenvironment, expansion of immunoregulatory cells, and activation of immune checkpoint pathways, all leading to T cell dysfunction and/or exhaustion. Leukemic cells, similar to other tumor cells, hijack these inhibitory pathways to evade immune recognition and destruction by cytotoxic T lymphocytes. Thus, blockade of immune checkpoints has emerged as a highly promising approach to augment innate anti-tumor immunity in order to treat malignancies. Most evidence for the clinical efficacy of this immunotherapeutic strategy has been seen in patients with metastatic melanoma, where anti-CTLA-4 and anti-PD-1 antibodies have recently revolutionized treatment of this lethal disease with otherwise limited treatment options. To meet the high demand for new treatment strategies in acute leukemia, clinical testing of these promising therapies is commencing. Herein, we review the biology of multiple inhibitory checkpoints (including CTLA-4, PD-1, TIM-3, LAG-3, BTLA, and CD200R) and their contribution to immune evasion by acute leukemias. In addition, we discuss the current state of preclinical and clinical studies of immune checkpoint inhibition in acute leukemia, which seek to harness the body’s own immune system to fight leukemic cells.

KW - Acute lymphoblastic leukemia

KW - Acute myeloid leukemia

KW - Co-inhibitory receptor

KW - Immune checkpoint pathway

KW - Immune evasion

KW - Immunotherapy

KW - Monoclonal antibody

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=85012075637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012075637&partnerID=8YFLogxK

U2 - 10.2174/1389450116666150518095346

DO - 10.2174/1389450116666150518095346

M3 - Review article

VL - 18

SP - 315

EP - 331

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 3

ER -